BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Novo Nordisk Shares Drop as Eli Lilly’s Weight-Loss Drug Shows Promise
Novo Nordisk Shares Drop as Eli Lilly’s Weight-Loss Drug Shows Promise
15
3
BTCCSquare news:
Novo Nordisk (NVO) shares fell nearly 2% Tuesday as Eli Lilly unveiled strong trial results for its oral weight-loss drug orforglipron, posing a direct challenge to Novo's blockbuster Wegovy. The GLP-1 treatment demonstrated 10.5% average body weight reduction and significant blood sugar improvements in Phase 3 trials.
Lilly's pill-form delivery gives it a potential competitive edge over injectable rivals. The news dampened sentiment toward Novo Nordisk even as broader markets edged higher, with the healthcare sector absorbing implications of intensified competition in the lucrative obesity drug market.
By:
